Penetrance and Prevalence Parameters
The age-specific incidence of colorectal and endometrial tumors among MLH1 and MSH2 carriers has been reported by a number of studies. Some studies ascertained families with multiple cancer cases, without proper correction of ascertainment bias, they are vulnerable to upward biases in the risk estimate. Thus, we estimated the cancer risk via a meta-analysis using only the population-based studies 1, 2, 3 and one additional analysis that adjusted for ascertainment 4 . The cancer incidence among population-based MSH6 carriers was only recently studied 3, 5 . We abstract MSH6 penetrance from those reports. We derived mean cumulative risks by 10-year age intervals. At each interval, the mean is a weighted average of risks from applicable studies, the weights are calculated according to the widths of study-reported confidence intervals. For cancer risks among non-carriers, we use the SEER registry, which publishes authoritative and comprehensive cancer incidence data from 11 populationbased registries throughout the US 6 .
We summarize the results of our meta-analysis of penetrance in Figure A1 . These results provide the default values used in the current version of MMRpro and all analyses in this article. These penetrance curves are also used to calculate the probability of developing CRC and EC for unaffecteds.
To Estimates of all quantities on the right hand side can be found in the literature. We consider only colorectal cancers diagnosed before age 50. A population-based estimate of the prevalence of MLH1 and MSH2 carriers among CRC cases younger than 50 is available 7 . After accounting for the sensitivity of the germline testing techniques used, the prevalence among younger cases is estimated to be 0.28. The overall cancer incidence by age 50 in the general population is 0.00215, from the SEER registry. The CRC risk among carriers of MLH1 and MSH2 (by age 50) is 0.32 according to the penetrance estimates reported earlier. The resulting carrier frequency is 0.0019 for MLH1 and MSH2 combined, or 0.0009 and 0.0010 for the two genes individually. Less information is available on MSH6 mutation prevalence. In MMRpro we assume that it accounts for 15% of all HNPCC mutations, that is, 0.00036. This prevalence may be population specific 8, 9, 10 
Sensitivity and specificity of MSI Testing
Results of MSI testing of tumors in any family member are incorporated into the Mendelian calculation by considering them part of an individual's phenotype information. This enters the calculations via the "probability of tumor characteristic given the individual's genotype", which in this case is a function of the sensitivity or specificity of the tumor markers in predicting a germline mutation.
MSI-h tumor results are predictive of germline mutation in MMR genes 10 Abnormal IHC is reported to be highly correlated with MSI [29] [30] [31] , with the added value of predicting the gene in which the mutation resides. It should be noted that the specificity of IHC and MSI may decrease with age, as somatic hyper-methylations accumulate. However, age-specific specificities are not implemented in the current version.
Sensitivity of conventional mutation detection techniques
Currently, the most widely used germline testing technique is direct sequencing. This, along with other conventional mutation detection assays, such as protein truncation 32 , conformation sensitive gel electrophoresis and allele-specific oligonucleotide testing 33 , direct sequencing can miss large genome rearrangements, deletions and duplications, which constitute a significant portion of MMR gene mutations. In the meta-analysis of 16 published studies, using the Hui and Walter approach 34 , by
grouping the tested population into a high-risk group and a low risk group, tabulating mutation analysis results against MSI result, we estimate that these mutation analysis techniques have a sensitivity of 62% (56-68%) in detecting pathogenic mutations 35 . This estimate is consistent with evidence arising from recent technologies such as conversion, which revealed a large number of mutations not detected before 27,36,37,38. After specifying sensitivity and specificity (the specificity of direct sequencing is assumed to be 100%), the results of germline testing of any member within the family can be incorporated in the same manner as MSI results. In practice, an individual with a high pre-germline test probability of being a carrier, who has an inconclusive sequencing test may still harbor a mutation missed by sequencing, and, thus, often has a high post-test carrier probability. 4 , Hampel et al. 2 and Jenkins et al. 3 , penetrance for MSH6 is based on Buttin et al. 17 
